GABA deficits enhance the psychotomimetic effects of Δ 9-THC

Neuropsychopharmacology

Volumn 40, Issue 8, 2015, Pages 2047-2056

  Radhakrishnan, Rajiv ^a,b,c   Skosnik, Patrick D ^a,c   Cortes Briones, Jose ^a,b,c   Sewell, R Andrew ^a,b,c   Carbuto, Michelle ^a,b,c   Schnakenberg, Ashley ^a,b,c   Cahill, John ^a,c   Bois, Fred ^a,c   Gunduz Bruce, Handan ^a,c   Pittman, Brian ^b,c   Ranganathan, Mohini ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Abraham Ribicoff Research Facilities   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DRONABINOL; FLUMAZENIL; IOMAZENIL; PSYCHOTROPIC AGENT;

ADULT; ANXIETY; ARTICLE; CANNABIS USE; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; GABAERGIC SYSTEM; HUMAN; MALE; NEUROLOGIC EXAMINATION; NORMAL HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; BRAIN MAPPING; CHEMICALLY INDUCED; DEFICIENCY; DISSOCIATIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN MAPPING; DISSOCIATIVE DISORDERS; DOUBLE-BLIND METHOD; DRONABINOL; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; FLUMAZENIL; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84930817826     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.58     Document Type: Article

References (53)

1. Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC (2011). Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 36: 677-683.
2. Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL (2008). Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 65: 1269-1274.
3. Bartos M, Elgueta C (2012). Functional characteristics of parvalbumin-and cholecystokinin-expressing basket cells. J Physiol 590: 669-681.
4. Beer HF, Blauenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I et al (1990). In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 31: 1007-1014.
5. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D et al (2012). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 17: 1152-1155.
6. Bhattacharyya S, Iyegbe C, Atakan Z, Martin-Santos R, Crippa JA, Xu X et al (2014). Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. Psychol Med 44: 3315-3328.
7. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004). Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 70: 315-329.
8. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136.
9. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV et al (1997). Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 154: 56-63.
10. Caspi A, Moffitt TE, Cannon M, McClay R, Harrington H et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117-1127.
11. Charych EI, Liu F, Moss SJ, Brandon NJ (2009). GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 57: 481-495.
12. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72: 811-816.
13. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594-608.
14. D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N et al (2012). Dose-related modulation of eventrelated potentials to novel and target stimuli by intravenous Delta(9)-THC in humans. Neuropsychopharmacology 37: 1632-1646.
15. D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS et al (2006). gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry 59: 128-137.
16. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
17. Dorow R, Horowski R, Paschelke G, Amin M (1983). Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 2: 98-99.
18. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA (2010). Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 169: 1651-1661.
19. Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C et al (2010). Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology 151: 5818-5829.
20. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-Patient Edition. American Psychiatric Association: Washington, DC.
21. Friedman D, Simpson G, Hamberger M (1993). Age-related changes in scalp topography to novel and target stimuli. Psychophysiology 30: 383-396.
22. Glausier JR, Fish KN, Lewis DA (2014). Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. Mol Psychiatry 19: 30-36.
23. Gratton G, Coles MG, Donchin E (1983). A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol 55: 468-484.
24. GROUP (2011). (Genetic, Risk Outcome in Psychosis, Investigators) Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 68: 138-147.
25. Gueorguieva R, Krystal JH (2004). Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 310-317.
26. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M et al (2006). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31: 2748-2757.
27. Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA et al (2010). Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 196: 447-453. Hoffman-La Roche-Data on File.
28. Hoffman-La Roche-Data on File. Horowski R, Dorrow R (2002). Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man. Psychopharmacology (Berl) 162: 223-224.
29. Hunkeler W, Mohler H, Pieri L, Polc P, Bonetti EP, Cumin R et al (1981). Selective antagonists of benzodiazepines. Nature 290: 514-516.
30. Jeon YW, Polich J (2003). Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40: 684-701.
31. Johnson EW, Woods SW, Zoghbi S, McBride BJ, Baldwin RM, Innis RB (1990). Receptor binding characterization of the benzodiazepine radioligand 125I-Ro16-0154: potential probe for SPECT brain imaging. Life Sci 47: 1535-1546.
32. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 59-67.
33. Klausberger T, Marton LF, O'Neill J, Huck JH, Dalezios Y, Fuentealba P et al (2005). Complementary roles of cholecystokinin-and parvalbumin-expressing GABAergic neurons in hippocampal network oscillations. J Neurosci 25: 9782-9793.
34. Lewis DA, Curley AA, Glausier JR, Volk DW (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35: 57-67.
35. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
36. Liang J, Cagetti E, Olsen RW, Spigelman I (2004). Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. J Pharmacol Exp Ther 310: 1234-1245.
37. Linszen D, van Amelsvoort T (2007). Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 20: 116-120.
38. Luck SJ, Mathalon DH, O'Donnell BF, Hamalainen MS, Spencer KM, Javitt DC et al (2011). A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry 70: 28-34.
39. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328.
40. Radhakrishnan R, Wilkinson ST, D'Souza DC (2014). Gone to Pot-A review of the association between cannabis and psychosis. Front Psychiatry 5: 54.
41. Randall P (1995). Iomazenil effects in PTSD patients and controls. In: personal communication D'Souza C (ed).
42. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM (2008). Effects of acute oral Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18: 569-577.
43. Schubiger P, Hasler P (eds) (1989). Iomazenil and other brain receptor tracers for SPECT. Proceedings of the Sixth Bottstein Colloquim. Wurenlingen/Villigen, Switzerland.
44. Shaw LM, Edling-Owens J, Mattes R (1991). Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemicalionization mass spectrometry. Clin Chem 37: 2062-2068.
45. Tallman JF, Gallager DW (1985). The GABA-ergic system: a locus of benzodiazepine action. Annu Rev Neurosci 8: 21-44.
46. Uhlhaas PJ, Pipa G, Lima B, Melloni L, Neuenschwander S, Nikolic D et al (2009). Neural synchrony in cortical networks: history, concept and current status. Front Integr Neurosci 3: 17.
47. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002). Cannabis use and psychosis: a longitudinal populationbased study. Am J Epidemiol 156: 319-327.
48. van Winkel; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011a). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 68: 148-157.
49. vanWinkel R, van Beveren NJ, Simons C;, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011b). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology, 36, 2529-2537.
50. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A et al (1999). [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 91: 163-173.
51. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2009). Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int J Neuropsychopharmacol 12: 357-370.
52. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296: 678-682.
53. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Ragland JD et al (2010). GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 30: 3777-3781.